Uni-Logo
ZHG-Logo
Zentrum für Humangenetik Bremen

Universität Bremen, Leobener Str. ZHG, D-28359 Bremen



Wir über uns Mitarbeiter Kontakt Genetische Beratung Diagnostik Forschung Publikationen Lehre Schulen
News Links Home Haftungsausschluss Impressum Research Disclaimer                
   


Publikationen
Publikationen der letzten 5 Jahre (Publications of the last 5 years)


Ältere Publikationen sind im Archiv zu finden.
Older publications may be found in the archive.
2010
  • Bullerdiek J, Rommel B (2010). Comment Re: HMGA2 is a negative regulator of DNA-PK pathway. Cancer Res. 10:1742.

  • Klemke M, Meyer A, Hashemi Nezhad M, Belge G, Bartnitzke S, Bullerdiek J (2010). Loss of let-7 binding sites resulting from truncations of the 3' untranslated region of HMGA2 mRNA in uterine leiomyomas. Cancer Genet. Cytogenet 196:119-123.



2009

  • Bullerdiek J, Helmke BM (2009). Comment on 'HMGA2, MicroRNAs, and Stem Cell Aging'. Cell Online Comment

  • Fehr A, Meyer A, Heidorn K, Röser K, Löning T, Bullerdiek J (2009). A link between the expression of the stem cell marker HMGA2, grading, and the fusion CRTC1-MAML2 in mucoepidermoid carcinoma. Genes Chromosomes Cancer 48:777-785.

  • Fehr A, Stenman G, Bullerdiek J, Löning T (2009). Molecular markers in salivary gland tumors: Their use in diagnostic and prognostic workup. Pathologe 30:466-471.

  • Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, Zhang Q, Bullerdiek J, Nolte I, Szalay AA (2009)(online 2008). Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther 16:320-328.

  • Hauschild G, Muschter N, Richter A, Ahrens H, Gosheger G, Fehr M, Bullerdiek J (2009). Cartilage replacement in dogs. Vet Comp Orthop Traumatol 22:216-221.

  • Klemke M, Meyer A, Hashemi Nezhad M, Bartnitzke S, Drieschner N, Frantzen C, Schmidt E-H, Belge G, Bullerdiek J (2009)(online 2008). Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer 48:171-178. 

  • Lacbawan F, Solomon BD, Roessler E, El-Jaick K, Domené S, Vélez JI, Zhou N, Hadley D, Balog JZ, Long R, Fryer A, Smith W, Omar S, McLean SD, Clarkson K, Lichty A, Clegg NJ, Delgado MR, Levey E, Stashinko E, Potocki L, Vanallen MI, Clayton-Smith J, Donnai D, Bianchi DW, Juliusson PB, Njølstad PR, Brunner HG, Carey JC, Hehr U, Müsebeck J, Wieacker PF, Postra A, Hennekam RC, van den Boogaard MJ, van Haeringen A, Paulussen A, Herbergs J, Schrander-Stumpel CT, Janecke AR, Chitayat D, Hahn J, McDonald-McGinn DM, Zackai EH, Dobyns WB, Muenke M (2009). Clinical spectrum of SIX3-associated mutations in holoprosencephaly: correlation between genotype, phenotype and function. J Med Genet 46:389-398.

  • Mohamed SA, Sievers HH, Hanke T, Richardt D, Schmidtke C, Charitos EI, Belge G, Bullerdiek J (2009). Pathway analysis of differentially expressed genes in patients with acute aortic dissection. Biomark Insights 4:81-90.

  • Pavlova A, Brondke H, Müsebeck J, Pollmann H, Srivastava A, Oldenburg J (2009). Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost 7:976-982.

  • Petersen S, Soller JT, Wagner S, Richter A, Bullerdiek J, Nolte I, Barcikowski S, Murua Escobar H (2009). Co-transfection of plasmid DNA and laser-generated gold nanoparticles does not disturb the bioactivity of  GFP-HMGB1 fusion protein. J Nanobiotechnology 7:6.

  • Richter A, Hauschild G, Murua Escobar H, Nolte I, Bullerdiek J (2009)(online 2008). Application of high-mobility-group-A proteins increases the proliferative activity of chondrocytes in vitro. Tissue Eng  Part A 15:473-477.

  • Sterenczak KA, Willenbrock S, Barann M, Klemke M, Soller JT, Eberle N, Nolte I, Bullerdiek J, Murua Escobar H (2009)(online 2008). Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene 434:35-42.

  • Verdorfer I, Fehr A, Bullerdiek J, Scholz N, Brunner A, Krugmann J, Hager M, Haufe H, Mikuz G, Scholtz A (2009). Chromosomal imbalances, 11q21 rearrangement and MECT1-MAML2 fusion transcript in mucoepidermoid carcinomas of the salivary gland. Oncol Rep 22:305-11.

  • Winter N, Meyer A, Richter A, Krisponeit D, Bullerdiek J (2009). Elevated levels of HMGB! in cancerous and inflammatory effusions. Anticancer Res 29:5013-5017.
2008

  • Altmann S, Lange S, Pommerencke J, Murua Escobar H, Bullerdieck J, Nolte I, Freund M, Junghanss C (2008). High Mobility Group Box 1-Protein expression in canine haematopoietic cells and influence on canine peripheral blood mononuclear cell proliferative activity. Vet Immunol Immunpathol 126:367-372.

  • Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S, Bullerdiek J (2008).Upregulation of HMGA2 in thyroid carcinomas: A novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 47:56-63.

  • Beuing C, Soller JT, Muth M, Wagner S, Dolf G, Schelling C, Richter A, Willenbrock S, Reimann-Berg N, Winkler S, Nolte I, Bullerdiek J, Murua Escobar H (2008). Genomic characterisation, chromosomal assignment and in vivo localisation of the canine high mobility group A1 (HMGA1) gene. BMC Genet 9:49.

  • Fehr A, Röser K, Heidorn K, Hallas C, Löning T, Bullerdiek J (2008). A new type of MAML2 fusion in mucoepidermoid carcinoma. Genes Chromosomes Cancer 47:203-206.

  • Fehr A, Röser K, Belge G, Löning T, Bullerdiek J (2008). A closer look at Warthin tumors and the t(11;19). Cancer Genet Cytogenet 180:135-139.

  • Fork MAM, Murua Escobar H, Soller JT, Sterenczak KA, Willenbrock S, Winkler S, Dorsch M, Reimann-Berg N, Hedrich HHJ, Bullerdiek J, Nolte I (2008). Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC Cancer 8:240.

  • Hafner C, Vogt T, Landthaler M, Müsebeck J (2008). FGFR3 and PIK3CA mutations are present in familial seborrheic keratoses. Br J Dermatol 159: 214-217.

  • Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C, Bullerdiek J (2008). Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 49:1184-1189.

  • Reimann-Berg N, Murua Escobar H, Nolte I, Bullerdiek J (2008). Testicular tumor in an XXY dog. Cancer Genet Cytogenet 183:114-116.

  • Soller JT, Beuing C, Murua Escobar H, Winkler S, Reimann-Berg N, Drieschner N, Dolf G, Schelling C, Nolte I, Bullerdiek J (2008).Chromosomal assignment of canine THADA gene to CFA 10q25.Mol Cytogenet 1:11.

  • Von Ahsen I, Nimzyk R, Klemke M, Bullerdiek J (2008). A microRNA encoded in a highly conserved part of the mammalian HMGA2 gene. Cancer Genet Cytogenet 187:43-44.

  • Winter N, Neumann A, Bullerdiek J (2008). Cell-free DNA in amniotic fluid remains to be attached to HMGA2 - implications for non-invasive prenatal diagnosis. Prenat Diagn 28:1126-1130.
2007

  • Drieschner N, Kerschling S, Soller JT, Rippe V, Belge G, Bullerdiek J, Nimzyk R (2007). A domain of the thyroid adenoma associated gene (THADA) conserved in vertebrates becomes destroyed by chromosomal rearrangements observed in thyroid adenomas. Gene 403:110-117.

  • Jensen J, Simon D, Murua Escobar H, Soller JT, Bullerdiek J, Beelitz P, Pfister K, Nolte I (2007). Anaplasma phagocytophilum in dogs in Germany. Zoonoses Public Health 54:94-101.

  • Meyer B, Krisponeit D, Junghanss C, Murua Escobar H, Bullerdiek J (2007). Quantitative expression analysis in peripheral blood of patients with chronic myeloid leukaemia: Correlation between HMGA2 expression and white blood cell count. Leuk Lymphoma 48:2008-2013.

  • Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J (2007). HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 46:503-511.

  • Ostersehlt D, Rippe V (2007). Drei Spritzen gegen Krebs. Unterrichtsmodell Sekundarstufe I/II Unterricht Biologie 330: 37-44.

  • Soller JT, Murua Escobar H, Willenbrock S, Janssen M, Eberle N, Bullerdiek J., Nolte I (2007). Comparison of the human and canine cytokines IL-1(α/ß) and TNF-α to orthologous other mammalians. J Heredity 98:485-490.

  • Winkler S, Murua Escobar H, Meyer B, Simon D, Eberle N, Baumgartner W, Loeschke S, Nolte I, Bullerdiek J (2007). HMGA2 expression in a canine model of prostate cancer. Cancer Genet Cytogenet 177:98-102.

2006

  • Bullerdiek J (2006). Moderne Methoden in der Genomforschung und Humangenetik (Research into the human genome driven by improved methods). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 49:989-994.

  • Drieschner N, Belge G, Rippe V, Meiboom M, Loeschke S, Bullerdiek J (2006). Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin. Thyroid 16:1091-1096.

  • Murua Escobar H, Soller JT, Sterenczak KA, Sperveslage JD, Schlueter C, Burchardt B, Eberle N, Fork M, Nimzyk R, Winkler S, Nolte I, Bullerdiek J (2006). Cloning and characterization of the canine receptor for advanced glycation end products. Gene 369:45-52.

  • Rooryck C, Roudaut C, Robine E, Müsebeck J, Arveiler B (2006). Oculocutaneous albinism with TYRP1 gene mutations in a Caucasian patient. Pigment Cell Res 19:239-242.

  • Soller JT, Murua Escobar H, Janssen M, Fork M, Bullerdiek J, Nolte I (2006). Cytokine genes single nucleotide polymorphism (SNP) screening analyses in canine malignant histiocytosis. Anticancer Res 26:3417-3420.

  • Von Ahsen I, Rogalla P, Bullerdiek J (2006). Germ line mutations of the HMGA2 gene are rare among the general population. Anticancer Res 26:3289-3292.

  • Winkler S, Reimann-Berg N, Murua Escobar H, Loeschke S, Eberle N, Höinghaus R, Nolte I, Bullerdiek J (2006). Polysomy 13 in a canine prostate carcinoma underlining its significance in the development of prostate cancer. Cancer Genet Cytogenet 169:154-158.





Top